Kronos Bio, Inc.
We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Our lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that has been tested in 148 acute myeloid leukemia (AML) patients. Based on clinical results in a biomarker-defined subset of patients and subject to discussions with regulatory agencies that we intend to have in the first half of 2021, we plan to initiate a registrational Phase 2/3 clinical trial in 2021 in newly diagnosed AML patients with NPM1 mutations, with an anticipated data readout in 2023.
|Address||1300 So. El Camino Real, Suite 300 San Mateo, California 94402|
|Phone Number||(650) 781-5200|
|View Prospectus:||Kronos Bio, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-25.1 mil (last 12 months)|
|Price range||$19.00 - $19.00|
|Est. $ Volume||$250.0 mil|
|Manager / Joint Managers||Goldman Sachs/ Jefferies/ Cowen and Company/ Piper Sandler|
|Expected To Trade:||10/9/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|